The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era by Morgan, C et al.
Original article
The influence of behavioural and psychological
factors on medication adherence over time
in rheumatoid arthritis patients: a study in the
biologics era
Catharine Morgan1, John McBeth1,2, Lis Cordingley3, Kath Watson1,
Kimme L. Hyrich1,4, Deborah P. M. Symmons1,4 and Ian N. Bruce1,4
Abstract
Objectives. To investigate levels of self-reported adherence to biologic treatment and establish the con-
tribution of demographic, physical and psychological factors to biologic medication adherence in an RA
cohort.
Methods. Adalimumab-treated patients were recruited through the British Society for Rheumatology
Biologics Register for RA between May 2007 and April 2009. Demographic and baseline psychological
measures including illness and medication beliefs were collected. Disease activity (28-item DAS), physical
function (HAQ) and quality of life (36-item Short Form Health Survey) were also measured at baseline and
at 6, 12 and 18 months. Adherence was assessed at each follow-up using the patient self-completed
Compliance Questionnaire for Rheumatology (CQR). Multilevel mixed effects modelling analysis was per-
formed to investigate predictors of adherence.
Results. Of the 329 Adalimumab-treated patients included, low adherence (CQR score <65) was reported
in 23%, with 41% reporting low adherence at at least one time point. After controlling for age and disease
duration, factors independently predictive of increased adherence were increased belief in medication
necessity, with baseline effect diminishing over time [b coefficient 1.68 (S.E. 0.19), P= 0.0001], lower
medication concerns [0.50 (0.15), P= 0.001], with this effect remaining throughout follow-up, increased
professional or family member support [0.81 (0.32), P= 0.01], strong views of illness being chronic [0.32
(0.14), P= 0.025] and increased treatment control [0.41 (0.19), P= 0.032].
Conclusion. Wider recognition of the importance of psychological factors, particularly medication beliefs,
in driving medication adherence could have substantial clinical and health economic benefits in RA. The
psychological factors we have identified are putative targets for strategies to improve adherence in RA.
Key words: rheumatoid arthritis, medication adherence, biologic therapy, illness perceptions, medication
beliefs, epidemiology.
Rheumatology key messages
. A quarter of RA patients show only low to moderate adherence to adalimumab.
. Illness and treatment beliefs are the major influences on adherence to adalimumab among RA patients.
. Higher perceived support from health professionals and family may improve adherence to adalimumab in RA.
1Arthritis Research UK Centre for Epidemiology, Centre for
Musculoskeletal Research, Institute of Inflammation and Repair,
University of Manchester, Manchester Academic Health Science
Centre, Manchester, 2Research Institute for Primary Care & Health
Sciences, Keele University, Keele, 3Institute of Inflammation & Repair,
University of Manchester, Manchester Academic Health Science
Centre and 4NIHR Manchester Musculoskeletal Biomedical Research
Unit, Central Manchester University Hospital NHS Foundation Trust,
Manchester Academic Health Science Centre, Manchester, UK
Correspondence to: Ian N. Bruce, Arthritis Research UK Centre for
Epidemiology, Centre for Musculoskeletal Research, Institute of
Inflammation and Repair, Manchester Academic Health Sciences
Centre, University of Manchester, Manchester, UK.
E-mail: Ian.bruce@manchester.ac.uk
Submitted 21 August 2014; revised version accepted
26 February 2015
! The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in
any medium, provided the original work is properly cited.
RHEUMATOLOGY
Rheumatology 2015;54:17801791
doi:10.1093/rheumatology/kev105
Advance Access publication 13 May 2015
C
L
IN
IC
A
L
S
C
IE
N
C
E
Introduction
Medication adherence is defined as the extent to which a
patient’s behaviour in taking their medication corresponds
to agreed recommendations by their health care provider
[1]. More than one-third of therapies are not taken as rec-
ommended, irrespective of the seriousness of disease or
condition [2]. There is increasing recognition of lower ad-
herence even in symptomatic diseases such as RA with
medication adherence rates reported between 55% and
96% [36]. Little is known about biologic drug adherence
in RA, and studies are further limited as adherence rates
tend to be derived from proxy measures, including medi-
cation persistence (time from prescription initiation to pre-
scription discontinuation), drug survival or medication
possession ratios from administrative claims data [711].
With the wider use of biologic therapy in RA, together with
reported low medication possession ratios and persist-
ence rates suggested in RA in general, there is a clear
need to investigate adherence rates of biologic therapy
in real-world practice.
The impact of medication non-adherence may
be considerable; adherent patients have more favourable
outcomes [12], including better disease control, higher re-
mission rates and improved physical function [13, 14], as
well as lower rates of disease progression and escalation
to further aggressive treatment [15, 16]. Biologic therapies
also have high lifetime costs to the health care system
[17], and lower persistence to biologic therapy is asso-
ciated with higher non-pharmacy costs [18].
Adherence is recognized to require sustained behav-
ioural change, influenced by both environmental and psy-
chological factors. In RA, influences on adherence include
age [10, 14], ethnicity [19], socio-economic factors [5, 20],
complexity of treatment [21] and RA disease-specific fac-
tors such as inflammatory markers (ESR) and disease ac-
tivity; however, it is important to note that findings are not
consistent across studies. In other disease groups, the
important influences of patients’ illness perception and
medication beliefs on adherence behaviour [22, 23], as
directed by the extended Self-Regulatory Common
Sense Model (SR-CSM) of illness [24] and treatment [25]
have been highlighted. According to the SR-CSM, an in-
dividual’s illness perception, such as beliefs about dis-
ease consequences or perceived personal control,
influence coping, including self-management strategies,
in response to the perception of a health threat [24]. A
further extension to this model is the necessity-concern
framework [25], suggesting patients’ beliefs about their
medication, including the perceived need for and/or
concerns about medication use, are an influence on medi-
cation adherence behaviour.
The aim of the current study was to investigate the level
of adherence to a biologic therapy longitudinally using an
RA-specific measure of adherence. We also sought to de-
termine the relative contribution of demographic factors,
RA disease-specific influences and psychological behav-
ioural influences on adherence in a single prospective
cohort.
Methods
Setting and recruitment
Patients were recruited through the British Society for
Rheumatology Biologics Register for RA (BSRBR-RA), a
UK-wide RA prospective observational cohort study
established in 2001 to monitor the long-term safety of bio-
logic therapy use in RA [26, 27]. Patient eligibility for a
biologic drug followed existing National Institute for
Health and Care Excellence criteria which were: satisfying
1987 ACR classification criteria for RA [28], having active
disease with a 28-item DAS (DAS28) score [29] >5.1 and
failing two or more previous synthetic DMARDs
(sDMARDs), including MTX. All patients were clinically
diagnosed by their treating physician. It was the phys-
ician’s decision to initiate a biologic, as well as the
chosen biologic therapy, and no specific exclusion criteria
applied. The level of provision of information about the
biologic therapy or education about its use was based
on the centre’s routine practice and not contingent upon
the individual’s participation in the study. This substudy
focused on patients starting s.c. adalimumab (ADA) as
their first biologic drug between May 2007 and April
2009. This was the main biologic drug under active
recruitment to the study at this time. All patients gave
written informed consent prior to inclusion and this
study was approved by the North West Research Ethics
Committee (REC:MREC 00/8/053).
Data collection
Baseline (start of treatment)
After written informed consent was obtained, the local
centre provided the year of diagnosis, 1987 ACR criteria
fulfilled and the DAS28 score [29]. A dichotomized vari-
able was derived for an acute phase response from age-
and gender-adjusted upper limits of the normal range of
ESR [30] or CRP [31]. Patients provided date of birth,
gender, ethnicity, work status, smoking status and post-
code for calculation of socio-economic status using the
country-specific Index of Multiple Deprivation [3234].
Patients also returned the following self-reported ques-
tionnaires: Stanford HAQ [35]; 36-item Short Form
Health Survey (SF-36) [36] and the EuroQol five-
dimensions questionnaire (EQ-5D) [37] using transformed
weighted health state index scores [38] and dichotomizing
(50.516). Additional measures used were the Revised
Illness Perception Questionnaire (IPQ-R) [39], capturing
illness beliefs based on the SR-CSM [24], where higher
scores across domains are indicative of a greater sense of
symptomology, the acute long-lasting and cyclical nature
of the disease, understanding and ultimate consequence
of the disease, personal treatment control and a higher
emotional state. The higher scores on the Beliefs about
Medicines Questionnaire [25] are indicative of a stronger
feeling of medication need and concern towards medica-
tion use. Also used were the Hospital Anxiety and
Depression Scale (HADS) [40] and an adaptation of the
Daily Coping Inventory, which assesses the level of
coping based on the number of preclassified strategies
adopted by an individual [41].
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Follow-up
Patients were mailed follow-up questionnaires, including
the HAQ and SF-36, at 6-monthly intervals (6, 12 and 18
months). Postal reminders were sent at 2 weeks and a
further reminder with repeat questionnaire at 4 weeks for
baseline or follow-up non-returners. The local centre pro-
vided the DAS28 score.
Adherence
As the main outcome measure, adherence data were col-
lected at 6, 12 and 18 months after the baseline measures
were recorded. The 19-item Compliance Questionnaire for
Rheumatology (CQR) [42] has been validated against
other adherence measures [5, 6, 20], including the
Medication Events Monitoring system [43]. Patients rate
their agreement with 19 statements using a 4-point Likert
scale. The adjusted total score ranges from 0 to 100 (100
indicating the highest possible adherence) and is used as
a continuous scale.
Analysis
After assessing for attrition and assigning missing data as
missing at random, appropriate application of Multiple
Imputation for Chained Equations [44] for 40 imputations
provided the imputed datasets. Complete case (CC)
results are presented with reference to imputed findings
where appropriate.
Multilevel mixed effects modelling analysis was per-
formed on 329 individuals with CC baseline data to
describe the longitudinal relationship between adherence
(CQR score) and potential predictors [45]. This allowed for
within- and between-patient and follow-up variability of
adherence score over time. In addition, a mixed model
approach assumes data are missing at random, rather
than missing completely at random. This allows all indivi-
duals to be retained and their available data utilized,
whether or not complete, to address potential bias
issues. Sixty-two per cent of the total variance in the
CQR score was represented at patient level (unconditional
model: intraclass correlation 0.62, between-patient var-
iance 67.29, time variance 40.94).
Univariate analysis
Random intercept models were applied to each predictor
variable to determine their prognostic value, controlling for
age at follow-up, gender, social deprivation and disease
duration. Interaction terms between the effects of each
predictor on adherence at each follow-up period were
retained where significant. Each significant predictor
from the intercept models (P< 0.05) were further modelled
by including their random slope and then tested using
likelihood ratio tests. The inclusion of random slopes
was not warranted for all predictors.
Multivariate analysis
A multivariate model was determined by adding and
retaining any significant univariate factors with applicable
interactions (P< 0.05). Models returned maximum likeli-
hood estimators and their efficiency was assessed using
the Akaike’s Information Criterion. Further diagnostics
were performed by inspection of normality of residuals.
All analysis was performed using STATA 11.2
(StataCorp, College Station, TX, USA).
Results
Response rates
Of 713 patients commencing ADA, 557 (78.1%) returned a
baseline questionnaire (Fig. 1). A high response rate
(>75%) was maintained throughout the follow-up period.
No systematic differences were observed between ques-
tionnaire returners and non-returners, including gender,
age at disease onset and disease activity. More non-retur-
ners resided in the most socially deprived quartile [50/156
(32.1%) vs 102/557 (18.3%)], although in the final analysis
each quartile was well represented (Table 1).
Of the 557 patients returning questionnaires, 329
(59.07%) had complete-case data at baseline and were
included in the analysis. For each follow-up, those with a
complete CQR score contributed to the analysis. The miss-
ing CQR scores at follow-up were a combination of incom-
plete items needed to generate the CQR (6, 12 and 18
month follow-up; n= 30, 32 and 33, respectively) or return-
ing a completely unanswered CQR (6, 12 and 18 months
follow-up; n= 58, 67 and 88, respectively). More than 50%
of CQR scores were available in individuals switching or
stopping medication, with no pattern observed in those
with or without a CQR score during follow-up (supplemen-
tary Table S1, available at Rheumatology Online). The
imputed data consisted of 556 individuals (one observation
omitted because it was a severe outlier) and 40 imputations
over baseline and 3 follow-ups.
In the complete-case dataset at baseline there were
257/329 (78%) women with a mean age at symptom
onset of 44 years (S.D. 13) (Table 1). The majority were of
white British ethnicity and across all levels of social
deprivation (between 20% and 30% in each quartile).
Two hundred and fourteen (62.1%) were not working
due to either illness or retirement and 190 (57.1%) had
ever smoked.
The mean CQR score remained <75 over the follow-up.
After dividing CQR scores into quartiles, 56 (23.2%), 54
(23.7%) and 48 (23.3%) patients for 6, 12 and 18 months,
respectively, had adherence scores in the lowest quartile
(CQR score 4064) (Table 2). Variability was noted in indi-
viduals’ adherence score over time, such that 41% of
those returning all follow-ups (n= 59/143) reported a
CQR score of 4064 at least once over the course of the
follow-up.
Influence of demographic factors
Older age was the only demographic factor significantly
associated with an increase in the CQR score
[b coefficient 0.14 (S.E. 0.04), P= 0.001] (Table 3).
Influence of disease activity and physical disability
Concomitant sDMARD treatment with ADA was used in
287 (81.2%) patients. Individuals had a mean disease
1782 www.rheumatology.oxfordjournals.org
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duration of 11.6 years (S.D. 9.2). They had a high mean
baseline DAS28 score of 6.4 (S.D. 0.9) and 177 (53.8%)
had an increased acute phase response. At 6 months
the DAS28 score was 3.95 (S.D. 1.5), with this response
maintained over the follow-up. In parallel, the HAQ and
SF-36 Physical Component Summary (PCS) scores
improved over time with response to treatment (Table 1).
The DAS28, high acute phase reactants and HAQ score
FIG. 1 Questionnaire returners and response rates during 18 months of follow-up
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TABLE 1 Descriptive information of complete case base-
line data of adalimumab-treated RA patients
Variable Value
Age at onset, mean (S.D.), years 44.25 (13.26)
Age at registration, mean (S.D.),
years
55.92 (12.27)
Female gender, n (%) 257/329 (78.1)
Ethnicity, n (%)
White 320/329 (97.3)
Black African 0
Black British 1/329 (0.3)
Indian 3/329 (0.9)
Pakistani 1/329 (0.3)
Bangladeshi 0
Other 4/329 (1.2)
Social deprivation quartile, n (%)
1 (least deprived) 87/329 (26.4)
2 99/329 (30.0)
3 79/329 (24.0)
4 (most deprived) 64/329 (19.4)
Working status, n (%)
Working 125/329 (37.9)
Not working due to illness 84/329 (25.5)
Retired 120/329 (36.6)
Ever smoker, n (%), yes/no 190/329 (57.6)
Disease activity
Number of baseline sDMARDs,
n (%)
0 62/329 (18.8)
1 161/329 (48.9)
2 77/329 (23.4)
3 29/329 (8.8)
Disease duration, mean (S.D.),
years
11.60 (9.22)
Satisfy ACR criteria, n (%), yes/no 275/329 (83.6)
Morning stiffness, n (%), yes/no 312/329 (94.8)
Involvement of >3 joints, n (%),
yes/no
274/329 (83.3)
Involvement of hand joint, n (%),
yes/no
259/329 (78.7)
Symmetry, n (%), yes/no 272/329 (82.7)
Nodules, n (%), yes/no 120/329 (36.5)
RF positive, n (%), yes/no 217/329 (66.0)
Erosions on X-ray, n (%), yes/no 193/329 (58.7)
Swollen joint count (028), mean
(S.D.)
11 (6)
Tender joint count (028), mean
(S.D.)
16 (7)
Inflammatory marker, n (%), yes/
no
177/329 (53.8)
Disease activity score (09.3),
mean (S.D.)
Baseline 6.44 (0.94)
6 months (n= 295) 3.95 (1.52)
12 months (n= 278) 3.77 (1.59)
18 months (n= 257) 3.57 (1.53)
DAS patient global score (0100),
mean (S.D.)
73.13 (16.99)
Psychological factors
IPQ-R domains, mean (S.D.)
Disease identity (014) 6.44 (2.33)
Timeline acute/chronic (630) 26.03 (3.28)
Consequences (630) 23.18 (3.73)
(continued)
TABLE 1 Continued
Variable Value
Personal control (630) 18.76 (4.24)
Treatment control (525) 17.71 (2.50)
Illness coherence (525) 18.63 (3.57)
Timeline cyclical (420) 14.67 (2.89)
Emotional (630) 19.85 (4.38)
HADS (021), mean (S.D.)
Anxiety 7.57 (4.30)
Depression 6.79 (3.94)
BMQ (525), mean (S.D.)
Necessity 21.54 (2.68)
Concern 14.95 (3.42)
EQ-5D utility score >0.516,
n (%)
Baseline 174/329 (52.9)
6 months 231/289 (79.9)
12 months 215/267 (80.5)
18 months 212/256 (82.8)
EQ-5D (baseline) VAS health
today (0100), mean (S.D.)
45.56 (20.72)
EQ-5D (baseline) health in last
12 months, n (%)
Better 33/329 (10.0)
Same 101/329 (30.6)
Worse 195/329 (59.3)
Coping, mean (S.D.)
Problem focused (416) 12 (10, 13)
Emotionally focused (416) 10 (8, 12)
Support (family) (28) 7 (6, 8)
Support (religion) (14) 1 (1, 2)
Functional disability
HAQ (03), mean (S.D.)
Baseline (n= 329) 1.80 (0.62)
6 months (n= 273) 1.43 (0.77)
12 months (n= 255) 1.43 (0.77)
18 months (n= 247) 1.42 (0.77)
SF-36 baseline domains
(0100), mean (S.D.)
Physical function 26.87 (22.85)
Physical role 25.06 (25.31)
Bodily pain 27.47 (16.89)
General health 32.77 (19.10)
Vitality 25.76 (19.16)
Social 42.63 (24.96)
Emotional 53.17 (34.62)
Mental health 57.51 (20.48)
Physical Component
Summary, mean (S.D.)
Baseline (n= 329) 18.72 (9.41)
6 months (n= 277) 27.04 (13.02)
12 months (n= 255) 27.25 (13.32)
18 months (n= 245) 28.13 (13.42)
Mental Component Summary,
mean (S.D.)
Baseline (n= 329) 44.12 (11.30)
6 months (n= 277) 48.61 (12.53)
12 months (n= 255) 50.11 (11.69)
18 months (n= 245) 49.60 (11.92)
BMQ: Beliefs about Medicines Questionnaire; EQ-5D:
EuroQol five-dimension questionnaire; HADs: Hospital
Anxiety and Depression Scale; IPQ-R: Revised Illness
Perception Questionnaire; SF-36: 36-item Short Form
Health Survey; VAS: visual analogue scale.
1784 www.rheumatology.oxfordjournals.org
Catharine Morgan et al.
did not predict the CQR score over time, although longer
disease duration was associated with a lower adherence
score [b1 coefficient 0.15 (S.E. 0.06), P= 0.009] (Table 3).
Influence of illness cognitions and mood
From the illness perception measures, there were high
mean scores in patients’ awareness of the long-lasting
nature of RA [timeline 26.0 (S.D. 3.28)], with this domain
also predicting increased levels of adherence [b coeffi-
cient 0.56 (S.E. 0.15), P= 0.0001] (Tables 1 and 3).
Patients had a high coherent understanding of their illness
[mean 18.6 (S.D. 3.57)] and treatment control [mean 18.8
(S.D. 4.24)], with both baseline effects significantly increas-
ing the CQR score [b1 coefficient 0.49 (S.E. 0.14),
P= 0.0001 and 0.67 (S.E. 0.2), P= 0.001, respectively].
Individuals sought more professional/family support com-
pared with other coping strategies {median 7 [interquartile
range (IQR) 68]} (Table 1). This support was associated
with an increase in expected adherence [b1 coefficient
1.25 (S.E. 0.37), P= 0.001] (Table 3). Medication necessity
was high [mean 21.54 (S.D. 2.68)] and had an increasing
effect on the CQR score [b1 coefficient 1.88 (S.E. 0.19),
P= 0.0001)]. Increased medication concern was asso-
ciated with a reduced CQR score [b1 coefficient 0.64
(S.E. 0.16), P= 0.0005)], with a significant increase in
this effect between baseline and 6 months [0.52 (S.E.
0.17), P< 0.005] that remained during further follow-up
(Table 3).
In the imputed dataset, the importance of medication
beliefs was also observed in the univariate analysis.
Perceived health in the previous 12 months, utility score
(EQ-5D) and SF-36 PCS and Mental Component
Summary (MCS) scores were also significant univariately,
although with low coefficients (supplementary Table S2,
available at Rheumatology Online). Anxiety and depres-
sion scores from the HADS were not predictive of the
adherence score (Table 3).
Independent predictors of adherence
In a multivariate analysis of the CC and imputed (IM) data-
sets it was found that an increased belief in medication
necessity was a significant independent predictor of
adherence in both the CC [1.68 (S.E. 0.19), P= 0.0001]
and IM datasets [1.65 (S.E. 0.18), P= 0.0001], with this
baseline effect on the CQR score diminishing over time,
as indicated by the significant negative time interaction
(Table 4). High medication concerns were also predictive
of a lower CQR score [CC =0.50 (S.E. 0.15), P= 0.001;
IM =0.49 (S.E. 0.14), P= 0.05], with the effect remaining
important throughout follow-up. Increased professional or
family support was associated with an increased CQR
score [CC = 0.81 (S.E. 0.32), P= 0.01; IM = 0.87 (S.E. 0.28),
P= 0.002]. A stronger perceived view of their illness being
chronic [0.32 (S.E. 0.14), P= 0.025] and an increased feel-
ing of treatment control [0.41 (S.E. 0.19), P= 0.032] at
baseline also predicted an increased CQR score in the
CC dataset. Comparing the random intercept variance
of the final model and unconditional model [63.23 (S.E.
6.16) and 43.02 (S.E. 4.46), respectively] showed a poten-
tial 20% of individual variance in CQR score being
accounted for by medication and illness beliefs and the
patient adopting coping strategies at baseline. Weakened
influence of an individual’s baseline perception of their
chronicity of illness (timeline domain) and their perceived
treatment control on adherence over time were seen in the
imputed dataset.
To better understand the influence of medication
beliefs, we utilized the final CC model to determine pre-
dicted CQR scores over time using extreme values of
necessity and concern responses. Individuals showing
acceptance towards their medication (high necessity
and low concern) had a predicted CQR score of 78.7
(S.E. 2.0) at 6 months compared with 54.0 (S.E. 4.1) for
sceptical individuals (low necessity and high concern)
(Table 5).
Discussion
This study is one of the first longitudinal studies assessing
adherence to biologic therapy in RA patients using a self-
reported measure. More than 50% of individuals had a
CQR score <75, indicating compromised adherence.
The levels of adherence found were comparable to pre-
viously reported rates for oral sDMARDs using the same
CQR adherence measure [3, 4, 6, 20] and also support
observations of low adherence measured by ADA posses-
sion ratio or persistence [79]. To our knowledge, this is
the first study to investigate the relative contribution of
TABLE 2 Adherence as indicated by the CQR score over the follow-up
Follow-up period,
months
CQR total
score,
mean (S.D.)
CQR quartiles, n (%)
Least adherent Most adherent
4064 6574 7583 84+
6 (n= 241) 74.99 (10.40) 56 (23.24) 57 (23.65) 70 (29.05) 58 (24.07)
12 (n= 228) 74.96 (10.75) 54 (23.68) 57 (25.00) 57 (25.00) 60 (26.32)
18 (n= 206) 74.59 (10.54) 48 (23.30) 60 (29.13) 52 (25.24) 46 (22.33)
CQR: Compliance Questionnaire for Rheumatology.
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TABLE 3 Univariate random intercept models reflecting the predictors’ influence on CQR score in ADA-treated patients
Predictor
b0 intercept
constant,
coefficient (S.E.)
b1, coefficient
(S.E.)
Random intercept
variance,
estimate (S.E.)
Overall error
(residual variance),
estimate (S.E.)
Demographic
Age at questionnaire, years 67.19 (2.64) 0.14 (0.04)** 63.44 (6.17) 40.79 (2.12)
Gender, female 67.19 (2.64) 0.76 (1.19) 63.44 (6.17) 40.79 (2.12)
Social deprivation
Quartile 2 (least deprived) 67.19 (2.64) 1.40 (1.03) 63.44 (6.17) 40.79 (2.12)
Quartile 3 67.19 (2.64) 0.11 (1.39) 63.44 (6.17) 40.79 (2.12)
Quartile 4 (most deprived) 67.19 (2.64) 1.36 (1.48) 63.44 (6.17) 40.79 (2.12)
Ever smoked 66.99 (2.66) 0.43 (1.01) 63.29 (6.16) 40.86 (2.22)
Disease activity
Number of baseline sDMARDs 66.60 (2.85) 0.30 (0.58) 63.19 (6.16) 40.88 (2.22)
Disease duration 67.19 (2.64) 0.14 (0.06)* 63.44 (6.17) 40.79 (2.12)
Satisfy ACR criteria 67.72 (2.80) 0.78 (1.34) 63.17 (6.15) 40.88 (2.22)
Morning stiffness 64.89 (3.36) 2.43 (2.29) 63.03 (6.14) 40.87 (2.22)
Involvement in >3 joints 68.25 (2.83) 1.37 (1.32) 63.08 (6.14) 40.86 (2.22)
Involvement in hand joint 68.82 (2.77) 2.17 (1.20) 62.49 (6.10) 40.88 (2.22)
RF positive 66.96 (2.73) 0.30 (1.04) 63.28 (6.16) 40.87 (2.22)
Erosions on X-ray 67.14 (2.67) 0.04 (1.03) 63.28 (6.16) 40.87 (2.22)
DAS28 68.04 (2.76) 0.13 (0.14) 63.08 (6.32) 41.30 (2.43)
Presence of inflammation 67.50 (2.68) 0.68 (0.67) 62.45 (6.32) 41.68 (2.47)
Functional disability
HAQ 66.83 (2.65) 0.09 (0.49) 63.19 (6.17) 39.99 (2.24)
SF-36 domains
Physical function 67.34 (2.77) 0.002 (0.01) 63.87 (6.23) 40.47 (2.23)
Physical role 67.10 (2.68) 0.002 (0.009) 63.89 (6.23) 40.48 (2.23)
Bodily pain 66.86 (2.69) 0.007 (0.01) 63.83 (6.23) 40.48 (2.23)
General health 66.89 (2.68) 0.003 (0.01) 63.81 (6.21) 40.27 (2.20)
Vitality 66.87 (2.67) 0.01 (0.01) 63.61 (6.19) 40.58 (2.21)
Social 67.01 (2.70) 0.003 (0.01) 63.68 (6.23) 40.64 (2.25)
Emotional 66.83 (2.72) 0.004 (0.009) 63.47 (6.21) 40.68 (2.25)
Mental health + time interactions 66.84 (2.90) 0.005 (0.02) 63.05 (6.13) 40.00 (2.18)
Fup1*mental health Interaction
2 = 11.12,
P= 0.01
 0.03 (0.03)  
Fup2*mental health  0.05 (0.03)  
Fup3*mental health  0.06 (0.03)*  
Physical Component Summary 66.82 (2.77) 0.0003 (0.03) 63.90 (6.26) 40.42 (2.25)
Mental Component Summary 65.60 (2.89) 0.03 (0.03) 63.84 (6.25) 40.38 (2.25)
Psychological
IPQ-R
Disease identity 69.02 (2.93) 0.31 (0.21) 62.83 (6.12) 40.87 (2.22)
Timeline acute/chronic 52.24 (4.81) 0.56 (0.15)** 60.36 (5.92) 40.83 (2.22)
Consequences 61.49 (4.18) 0.23 (0.13) 62.60 (6.10) 40.87 (2.22)
Personal control 66.24 (3.49) 0.05 (0.12) 63.26 (6.16) 40.87 (2.22)
Treatment control 55.18 (4.45) 0.67 (0.20)** 60.73 (5.96) 40.88 (2.22)
Illness coherence 56.71 (3.91) 0.49 (0.14)** 60.42 (5.93) 40.86 (2.22)
Timeline cyclic 65.94 (3.56) 0.09 (0.17) 63.24 (6.16) 40.87 (2.22)
Emotional representation 63.11 (3.61) 0.19 (0.11) 62.54 (6.11) 40.90 (2.22)
HADS
Anxiety + time interaction 67.82 (2.83) 0.09 (0.13) 63.27 (6.15) 40.38 (2.19)
Fup1*anxiety Interaction
2 = 8.11,
P= 0.04
 0.32 (0.13)*  
Fup2*anxiety  0.04 (0.14)  
Fup3*anxiety  0.05 (0.14)  
Depression 68.07 (2.78) 0.13 (0.13) 63.04 (6.14) 40.87 (2.22)
BMQ
Necessity + time interaction 27.20 (4.77) 1.88 (0.19)** 48.16 (4.89) 39.77 (2.15)
Fup1*necessity Interaction
X2 = 16.12,
P= 0.001
 0.43 (0.21)*  
Fup2*necessity  0.54 (0.22)*  
Fup3*necessity  0.84 (0.22)**  
Concern + time interaction 77.20 (3.64) 0.64 (0.16)** 60.34 (5.91) 40.26 (2.19)
(continued)
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demographic factors and RA disease-specific and psy-
chological behavioural influences on adherence in a
single prospective cohort.
Increased perception of treatment control as an inde-
pendent predictor of increased adherence was indicative
of patients starting an injectable drug such as ADA and
retaining some sense of treatment control and high
expectations of the new medication [46]. The association
of coping through seeking professional/family support is
verified by findings from a meta-analysis of 122 studies
published between 1948 and 2001. Patients receiving
social support were 3.6 times more likely to adhere to
medication than those not receiving support [47]. The sup-
port may reflect the intense pretreatment counselling or
indicate patients moving into a more dependent phase of
their illness. However, little is known about the most effec-
tive type of coping and the association with adherence.
A key observation in our RA cohort was the major influ-
ence of patient beliefs on treatment adherence, seen also
in other chronic conditions including asthma, hyperten-
sion and chronic pain [23]. The necessity-concern frame-
work [25] suggests that a patient’s adherence decisions
are a result of the balance between their perceived need
for the medication (necessity) and their concerns regard-
ing its use. We were able to stratify individuals into spe-
cific treatment attitudes based on necessity and concern
and estimate the potential influence that combinations of
beliefs have on adherence. The importance of medication
necessity for new users of ADA regardless of concern
level was fundamental in predicting increased adherence
and requires further work in establishing the stability of
both beliefs over the treatment and disease pathway.
Several studies of oral sDMARD adherence, as well as
studies in other conditions, have also shown similar
importance of medication beliefs [4, 5, 23]. Non-
adherence may therefore owe more to individual patient
beliefs than to the actual disease or route of drug admin-
istration. A patient’s level of medication belief may of
course be influenced by the perceived intensity of the
drug and/or its mode of administration. However, our
data suggest that the influence on adherence remains
qualitatively similar across therapy types.
Our findings reflect those of other studies showing that
older age is associated with higher adherence [14]. Others
have found that increased age predicted early termination
of biologic therapy [10], although persistence studies may
measure stopping due to efficacy or adverse events rather
than adherence.
TABLE 3 Continued
Predictor
b0 intercept
constant,
coefficient (S.E.)
b1, coefficient
(S.E.)
Random intercept
variance,
estimate (S.E.)
Overall error
(residual variance),
estimate (S.E.)
Fup1*concern Interaction
X2 = 10.66,
P= 0.014
 0.52 (0.17)**  
Fup2*concern  0.17 (0.17)  
Fup3*concern  0.008 (0.17)  
EQ-5D
Health today 67.68 (2.71) 0.01 (0.01) 62.95 (6.15) 41.08 (2.24)
Utility group> 0.516 67.01 (2.67) 0.32 (0.59) 63.21 (6.18) 41.01 (2.24)
Coping
Problem focused 64.91 (3.40) 0.19 (0.18) 62.97 (6.14) 40.89 (2.22)
Emotionally focused 65.86 (3.08) 0.16 (0.19) 63.15 (6.15) 40.87 (2.22)
Family/professional support 59.65 (3.40) 1.25 (0.37)** 60.64 (5.95) 40.87 (2.22)
*P< 0.05; **P< 0.005. ADA: adalimumab; BMQ: Beliefs about Medicines Questionnaire; CQR: Compliance Questionnaire for
Rheumatology; DAS28: 28-joint DAS; EQ-5D: EuroQol five-dimensions questionnaire; Fup1: follow up at 6 months; Fup2:
follow up at 12 months; Fup3: follow up at 18 months; HADs: Hospital Anxiety and Depression Scale; IPQ-R: Revised Illness
Perception Questionnaire; SF-36: 36-item Short Form Health Survey.
TABLE 4 Final random intercept models of independent
predictors of CQR over time in adalimumab-treated
patients
Factors associated
with CQRa
Complete
case model Imputed model
b coefficient (S.E.)
b coefficient
(S.E.)
Necessity 1.68 (0.19)** 1.65 (0.18)**
Fup1*necessity 0.44 (0.21)* 0.46 (0.20)*
Fup2*necessity 0.54 (0.21)* 0.58 (0.20)**
Fup3*necessity 0.86 (0.22)** 0.64 (0.21)**
Concern 0.50 (0.15)** 0.49 (0.14)**
Fup1*concern 0.50 (0.17)** 0.31 (0.16)*
Fup2*concern 0.14 (0.17) 0.33 (0.16)*
Fup3*concern 0.05 (0.17) 0.04 (0.17)
Support 0.81 (0.32)* 0.87 (0.28)**
Timeline acute/chronic 0.32 (0.14)* 0.24 (0.13)
Treatment control 0.41 (0.19)* 0.27 (0.17)
Fup1 1.53 (5.17) 5.43 (4.84)
Fup2 9.55 (5.25) 8.84 (4.87)
Fup3 18.92 (5.48)** 14.67 (5.32)*
b0 intercept constant 18.44 (7.45) 23.00 (6.68)
2u0 intercept
variance (S.E.)
43.02 (4.46) 48.86 (4.82)
2E overall error
(residual) (S.E.)
39.18 (2.11) 55.92 (3.13)
aAdjusted for age, gender, disease duration and social depri-
vation. *P< 0.05; **P< 0.005. CQR: Compliance Question
naire for Rheumatology; Fup1: follow up at 6 months; Fup2:
follow up at 12 months; Fup3: follow up at 18 months.
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Measures of disease activity and functional disability
were not associated with adherence in our study, despite
high levels of disease activity and high HAQ scores at
baseline. Others have also noted that neither disease
duration nor disease activity (using ESR and CRP level)
were associated with adherence in RA [5]. In contrast,
Owen et al. [48] found increased ESR and morning stiff-
ness were associated with higher adherence in a univari-
ate analysis (as measured by interview). Our patients had
established disease and had a high perceived under-
standing of the cyclical nature of the disease, a high
level of illness coherence and adopted a large number
of coping strategies. This long-standing experience of
RA may have made them more aware of the implications
of further flares and thus to keep taking medication even
when feeling better. Also, our assessment of disease
activity and disability was sampled over a short period
of their overall disease experience. As such, it may have
little effect on whether a patient chooses to take his/her
medication at a specific time.
Our findings have important implications not only on
ultimately reducing the economic impact of non-
adherence to biologic therapies, but also in improving
routine clinical outcomes. First, it highlights the need for
clinicians to be vigilant for potential non-adherence in
patients taking biologic therapies. It also highlights the
important role of perceived health care support an indivi-
dual receives, thus the supportive and empathic aspects
of clinical practice should be enhanced. Our study has
identified potential modifiable patient beliefs. Clinicians
therefore need to address the patient’s perception of
medication need and concerns early in the treatment
course. Further, the diminishing effect of the necessity
belief over follow-up suggests that the need for medica-
tion should be reiterated throughout the treatment course.
There is, however, a clear dilemma at an individual level of
how patients judge personal need relative to the concern
about their medication which influences the motivation of
taking the medication. More than 40% of patients in this
study had a strong belief in the need for treatment but
simultaneously expressed strong concerns about medica-
tion use. Non-adherence is often the response to the
latter. Identifying and targeting this at-risk group may be
of particular value in improving overall clinical outcomes.
With the increasing use of biologic therapies, approaches
to improve adherence will likely reduce the economic
burden by reducing wastage of drugs and avoid further
drug escalation. Early evidence has shown promising
potential for an SR-CSM-related behaviour intervention
to target key cognitions [49]. Such inventions may be fea-
sible in a routine clinical consultation to improve adher-
ence and thus overall outcomes.
A study such as this has potential limitations. Missing
data are inevitable in large observational studies using
postal questionnaires. The majority of measures used
were composite scores, and unless the initial methodol-
ogy included a way to handle missing responses, the total
score was marked as missing. The analysis of missing
data only indicated that younger individuals had more
complete data. Patterns of missing data showed an
absence of monotone pattern and was indicative of an
arbitrary one, which was effectively approached using
Multiple Imputation for Chained Equations where appro-
priate. In addition, the mixed model methodology also
allowed all available follow-up data to be utilized without
missing scores having any effect on other available scores
for the same individual.
Accurately defining and measuring adherence is diffi-
cult. Some of the CQR items incorporating attitudinal con-
structs related to medication taking may potentially
confound the relationship between the medication belief
scale and adherence. At the time of study, the CQR was
the only validated RA adherence questionnaire.
Our study focused on patients starting ADA, because of
the time period in which patients were recruited from the
BSRBR-RA. There is some evidence that medication pos-
session ratios and persistence rates differ across biologic
therapies [8, 10, 11]. However, those studies did not use
the measures employed in this study, so observed varia-
bility may be due to adverse event profiles or efficacy
differences. However, our results do accord with observa-
tions in other chronic disease, suggesting they may be
generalized to other ambulatory drugs in RA. It is also
possible that our analyses were limited by illness and
medication beliefs not being captured beyond the base-
line visit. Few longitudinal studies have investigated the
stability of beliefs over time, although general beliefs in
non-prescribed analgesics have been shown to be
stable over time [50]. Thurah et al. [4] also noted in 65
new users of MTX that concern levels were stable over
TABLE 5 Predictive margins of CQR score during follow-up for levels of an individuals’ treatment belief
Individual
Baseline BMQ domain score Predicted CQR score (95% CI)
Necessity Concern 6 months 12 months 18 months
Accepting 25 5 78.74 (74.81, 82.67) 82.50 (78.53, 86.48) 82.89 (78.97, 86.82)
Ambivalent 25 25 78.85 (75.00, 82.69) 75.40 (71.47, 79.33) 71.93 (67.89, 75.96)
Indifferent 5 5 53.89 (46.07, 61.72) 59.62 (51.67, 67.56) 66.42 (58.17, 74.67)
Sceptical 5 25 54.00 (45.87, 62.11) 52.52 (44.23, 60.81) 55.46 (47.32, 63.60)
BMQ: Beliefs about Medicines Questionnaire; CQR: Compliance Questionnaire for Rheumatology.
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a 9-month period. Further larger longitudinal work addres-
sing changes in treatment beliefs would be advantageous
to inform on patients behavioural influences over time. In
addition, co-morbidities were not considered, which may
further impact on adherence by the increasing number of
medication regimes and the choice of one regime
over another for multiple conditions, thus influencing ill-
ness and medication concerns. Finally, the nature of
the study also prevented recording the influence of
the patientconsultant relationship and contact time,
the provision and extent of medication and disease infor-
mation and other patient factors such as self-efficacy,
which may be additional influences on medication
adherence.
In conclusion, a quarter of patients showed only low to
moderate adherence (CQR score <65) to ADA, a self-
administered injectable biologic therapy. Medication
beliefs (high concerns and low necessity beliefs) were
associated with lower adherence. Increased
professional/family support, stronger perceived illness
chronicity and an increased feeling of treatment control
also predicted adherence over time. These findings high-
light the need to prioritize the monitoring of biologic treat-
ment adherence in a chronic symptomatic disease group
such as RA.
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